Supporting agencies: This article has been supported by Materia Medica Holding. The clinical studies described in the publications [12, 14, 15, 48] were funded by a grant from LLC NPF Materia Medica Holding
For citations:
Perez M., Zavadenko N.N., Skipetrova L.A., Smirnov I.I., Nesterovskiy Yu.E. Efficacy and safety of a daytime anxiolytic containing technologically processed antibodies to the S100 protein. Overview of clinical studies. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(3):104-113. https://doi.org/10.14412/2074-2711-2023-3-104-113
Views: 43
Email this article 